Abstract
The Effect of Fedratinib, a Selective Inhibitor of Janus Kinase 2 (JAK2), on Weight and Metabolic Parameters in Patients with Intermediate (INT)- or High-risk Myelofibrosis (MF)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have